Protara Therapeutics, based in New York, develops treatments for rare diseases and is conducting Phase II trials for its lead candidate, TARA-002, in non-muscle invasive bladder cancer and lymphatic malformations. The company also works on IV Choline Chloride for patients needing parenteral nutrition.
Protara Therapeutics (TARA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Protara Therapeutics's actual EPS was -$0.50, beating the estimate of -$0.53 per share, resulting in a 5.73% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
